Completed PHASE4 INTERVENTIONAL 1-arm NCT03393767

Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD

Time Course of Activity Signs at High Resolution OCT During OCT-guided High Frequency Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Age Related Macular Degeneration

Sponsor: Vista Klinik

Conditions Age Related Macular Degeneration Choroidal Neovascularization

Interventions Ranibizumab

Updated 5 times since 2018 Last updated: Jan 2, 2018 Started: Dec 31, 2010 Primary completion: Oct 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03393767, this PHASE4 trial focuses on Age Related Macular Degeneration and Choroidal Neovascularization and remains completed. Sponsored by Vista Klinik, it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2018 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vista Klinik

Data source: Vista Klinik

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Binningen, Switzerland